Looks like Celgene are risking $100 upfront to partner with Prothena’s (Irish Biotech) Tau antibody programme

Tau targets are the latest alternative to amyloid

They are however ‘edging their bets’ by also putting $100 into Vividion programme to develop new small molecule treatments

<<<Celgene>>>